The pathogenesis of thrombocytopenia occurring after autologous stem cell transplantation (ASCT) remains unclear. Six cases of classical peripheral thrombocytopenia that developed after ASCT for non-Hodgkin's lymphoma (NHL) are presented. Resolution of this complication was obtained by usual treatment such as steroids, splenectomy or progressively resolved without specific treatment. Five out of six patients have been followed for more than 5 years after hematopoietic transplantation and are still alive in complete remission despite poor prognostic factors at diagnosis. Several arguments suggest that this phenomenon represents autoimmune thrombocytopenia and may be the consequence of an altered immune balance. Consequently, development of autoimmune reactions after bone marrow transplantation might be associated with an antitumoral effect (graft-versus-lymphoma effect). Bone Marrow Transplantation (2003) 32, 89-95.
Persistent thrombocytopenia is common after autologous stem cell transplantation (ASCT) performed with either peripheral blood or bone marrow hematopoietic cells, occurring immediately or later after engraftment. Several mechanisms may be involved including poor hematological recovery or various infections, but autoimmune cytopenia in this setting appears to be rare and can be life-threatening.
The pathogenesis of autoimmune thrombocytopenia after ASCT remains unclear. Infectious, genetic or environmental factors may participate in the development of autoimmune diseases but alteration of immune reconstitution seems to result in immunological dysregulation that may predispose to autoimmune events after ASCT. Few cases of endocrine, neurological immune disease or autoimmune cytopenia have been described after autologous marrow transplantation. 1, 2 We report here six patients who developed apparent autoimmune thrombocytopenia after ASCT performed for non-Hodgkin's lymphoma (NHL).
Patients and methods

Patients
Between 1990 and 1998, 277 patients had received a total of 307 ASCT for the treatment of lymphoid malignancy in our department. 3 Among these patients, 30 received two transplantations, essentially multiple myeloma patients. This population included 172 men and 105 women with a median age of 48 years (range . Patients with Hodgkin's disease (HD) (9%), NHL (77%) or multiple myeloma (14%) were selected for intensive chemotherapy because of relapse, first-line treatment failure or poor prognostic criteria at diagnosis. Patients with peripheral thrombocytopenia diagnosed after ASCT were identified in this database.
Disease status
Disease status was assessed at the time of ASCT harvest with clinical examination, computerized tomography (CT) or bone marrow biopsy. Most of the patients received autologous transplantation in partial response (63%) and a minority in complete response (31%) or with progressive disease (6%).
Peripheral Blood Stem Cells (PBSCs)
PBSCs were collected after high-dose chemotherapy (consisting essentially of cyclophosphamide 5.25 g/m 2 alone or cyclophosphamide 4.5 g/m 2 plus etoposide 450 mg/m 2 ) followed by hematopoietic growth factors in most patients. The median number of aphereses necessary to obtain a sufficient number of stem cells was three (range 1-7). ) (9%). PBSC were reinfused after the last day of conditioning regimen with TBI or 2 days after the end of chemotherapy.
PBSC transplantation
Hematological recovery
The absolute neutrophil count recovery time was defined as the number of days between progenitor cell reinfusion (day 0) and the time required to obtain a stable neutrophil count greater than 0.5 Â 10 9 /l. The time to platelets over 50 Â 10 9 /l was defined as the number of days from day 0 until platelets counts remained stable over 50 Â 10 9 /l for at least 3 days without platelet transfusion.
Patients were evaluated with clinical examination, CT scan, bone marrow aspirate or biopsy at 3 months and then regularly after transplantation.
Laboratory evaluation
Full blood counts and biochemistry (renal and liver function) were assessed. Viral serology (including cytomegalovirus, Epstein-Barr virus, hepatitis A, B or C and HIV) and CMV viremia were tested in patients' sera. Each patient who developed thrombocytopenia after ASCT underwent bone marrow aspiration (with particular attention to megakaryocyte numbers, dysplastic features or abnormal cellular infiltrates). In one case, antiplatelet autoantibodies were demonstrated using a MAIPA-test (monoclonal antibody-specific immobilization of platelet antigens). 4 Investigation of other autoimmune complications after ASCT were not performed.
Immunophenotype of peripheral blood cells
Peripheral blood mononuclear cell fractions (PBMCs) were separated by Fycoll-Hypaque sedimentation. The PBMCs were washed twice in phosphate-buffered saline (PBS) and resuspended in RPMI 1640, containing 2% fetal calf serum. Two color flow cytometric analysis of these cells was carried out using a FACs analyser equipped with a software program (CellQuest) (Becton Dickinson). The following monoclonal antibodies were used : CD2, CD3, CD4 , CD8, CD45RA, CD45RO and CD20.
Results
Six patients who had undergone ASCT were found to have persistent peripheral thrombocytopenia (platelet count o50 Â 10 9 /l) despite a normal hemoglobin level or granulocyte count.
Patients characteristics
All patients were treated with intensive chemotherapy because of NHL in relapse. No patient had a previous history of autoimmune disease before transplantation. There were three male and three female patients. Their median age was 45 years and five of the six patients were older than 40 years at the time of transplant (Table 1) . All these six patients were followed for NHL (follicular, mantle zone, anaplastic large cell, diffuse large cell or Burkitt lymphoma) without predominance of a particular histologic type. Some patients were heavily pretreated (more than three courses of chemotherapy). Two patients have been previously treated with fludarabine.
Autograft characteristics
Characteristics of patients according to intensive chemotherapy and autologous progenitor cell transplantation are summarized in Table 2 . At the time of harvest, five patients were in partial response. In all six patients, the number of PBSC reinfused (CFU-GM or MNC) was similar to the numbers of progenitor cells reinfused among the 277 patients of the entire cohort (for whom median numbers were 119 Â 10 4 or 3.52 Â 10 8 MNC/kg) ( Table 2 ). Conditioning regimens in these six patients consisted of cyclophosphamide-etoposide-TBI (n ¼ 4) or BEAM (n ¼ 2).
Complete neutrophil and platelet recovery were achieved within a median delay of 11 and 15 days respectively in these six patients, values that were comparable to those of the other patients (respectively 11 and 14 days).
Characteristics according to the autoimmune phenomena after ASCT
When it appeared, autoimmune thrombocytopenia was associated was hemorrhagic symptoms such as epistaxis or diffuse purpura. Low platelet counts were found in each patient (less than 20 000/mm 3 ) ( Table 3) . In most cases, this autoimmune thrombocytopenia occurred less than 1 year after ASCT (Table 4 ). In two cases (patients 3 and 4) thrombocytopenia occurred later (respectively 14 and 21 months after ASCT), but in the latter case, the patient received chemotherapy 1 year after transplantation because of relapse. In the first case, autoimmune neutropenia was suspected 2 months after ASCT and resolved with treatment by G-CSF. Autoimmune thrombocytopenia occurred 6 months later, after a viral bronchopneumonia. A suspected viral infection was also noted several days before the occurrence of autoimmune thrombocytopenia in another patient (case 3). In another case, the patient received immunization against influenza virus and presented severe autoimmune thrombocytopenia the day after (case 6).
In each case, diagnosis of autoimmune thrombocytopenic purpura was made with a confirmatory bone marrow aspiration and in the absence of any other aetiology (Table 3 ). Viral serological tests and CMV viremia were negative. Platelet-associated immunoglobulins were assessed in one patient, and detection of autoantibodies directed against GPIIb/IIIa was confirmed by an MAIPA test. Immunophenotyping of PBMC was performed in two cases (patients 1 and 6) before treatment of thrombocytopenia, respectively 2 and 6 months after ASCT. Decreased numbers of CD4+ lymphocytes (particularly CD4CD45RA naive subsets) and normal levels of CD8+ lymphocytes were shown by flow cytometry.
Treatment with corticosteroids produced complete resolution of thrombocytopenia in only one case (case 4) with a relapse 1 year later successfully treated with a second course of corticosteroid (Table 4) . Splenectomy was performed in three patients not responding to steroids, and was followed by a sustained increase in platelet counts without any relapse. In the last two patients (cases 1 and 5), steroid treatment needed to be prolonged and resolution of thrombocytopenia was observed after respectively 18 or 24 months. Most of the patients (5/6) who developed autoimmune thrombocytopenia have been followed more than 5 years.
Patients long-term outcome after autologous transplantation
Within a median follow-up of 6 years, no NHL relapse was noted in any of these cases (Table 5) . One patient died 2 years after ASCT because of bronchopulmonary cancer (case 6). All patients had poor prognostic factors 5 at diagnosis or at transplant (Table 5) , including advanced stage disease (all six patients), elevated LDH levels (three patients), massive marrow infiltration by lymphoma cells (two patients), bulky tumor or CNS involvement (one each) and three patients had progressive disease after first-line therapy.
Discussion
This report presents six cases of peripheral thrombocytopenia occurring after ASCT in lymphoma patients with usual features of autoimmune thrombocytopenia. Furthermore, five out of these six patients experienced long-term disease-free survival after ASCT despite poor prognostic factors. Several immune reactions may occur after ASCT such as immune thyroiditis, neurological immune disease (GuillainBarre´syndrome, myasthenia gravis) or immune cytopenia. 1 Moreover, spontaneous and experimental autologous graft-versus-host (GVH) disease after ASCT have been described. 6, 7 Development of an autoimmune phenomenon after ASCT is therefore not exceptional.
Autoimmune thrombocytopenias occurring de novo or after ASCT share similar clinical features. Severity of thrombocytopenia and methods of diagnosis are comparable. In each situation, diagnosis is made by bone marrow aspiration, demonstrating peripheral thrombocytopenia, while any other known etiology should be eliminated. Characterization of autoantibodies directed against platelet glycoproteins does not appear as a major criterion for the diagnosis. Moreover, the same standard therapies are used in each situation. These immune complications after ASCT occur without predominant underlying disease and have already been described after myeloid leukemia, 8 multiple myeloma 9 or NHL.
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These six patients who developed autoimmunity did not have any particular feature according to the characteristics of transplantation such as conditioning regimen, number of aphereses, number of stem cells reinfused, hematopoietic or immunological recovery. Consequently, in these patients, development of immune thrombocytopenia might be related to disturbances induced by the transplantation itself or by immune reconstitution after ASCT. Since only isolated cases of autoimmunity are reported after ASCT, we can suppose that immunological events involved in the process of immune reconstitution itself are not sufficient to permit development of this autoimmune phenomenon.
In autoimmune diseases occurring de novo, breakdown of tolerance implies altered recognition of self-antigens by autoreactive T lymphocytes and disruption of normal immunoregulatory mechanisms. In the ASCT setting, selfrecognition by autoreactive lymphocytes or subsequent reactivation of autoreactive cells while the recovery of regulatory T cells is delayed or while suppressive functions are impaired might constitute the underlying mechanisms for development of autoimmunity.
Several hypotheses have been proposed to explain how altered expression of self-antigens leads to autoimmune recognition. Stem cells may undergo physical damage during transplantation, specially during handling procedures such as filtration or freezing. 2 After intensive chemotherapy and during hematopoietic recovery, platelet microparticles may be produced carrying altered selfantigens. 11 Molecular mimicry mechanisms may also be induced by viral infections during the post-transplant period when viral antigens alone or combined with self leads to recognition of platelet antigens as foreign antigens. Post-transplant autoimmune cytopenia have been reported during infections such as cytomegalovirus, 12,13 pericarditis or mycobacteriosis. 12 However, triggering by infection does Autoimmune thrombocytopenic purpura ASCT O Hequet et al not appear to be necessary for the development of autoimmunity since many cases described in the literature as well as three cases in the present series did not have evidence of an active concomitant infection.
Vaccine or viral antigens may also act as potent polyclonal activators for autoreactive lymphocytes. In case 6, thrombocytopenia occurred immediately after vaccination. In this series, two of our patients were also treated by a-interferon, which is able to induce polyclonal T stimulation and immune thrombocytopenia. 14 The development of autoimmunity after ASCT also suggests a decrease of immune regulatory mechanisms in patients. This mechanism has also been suspected to participate in the physiopathology of chronic idiopathic thrombocytopenic purpura in adults. 15, 16 Suppressor T cells include some CD8+ T cells 17 and some CD4+ T cells such as CD4 TR1 lymphocytes or CD4+CD25+ lymphocytes recently described. 18 When flow cytometric analyses have been performed in the setting of ASCT, in the present two cases or in other studies, 8 differential counts of CD3, CD4 or CD8 were found to vary according to the delay after transplantation. Effector cells such as CD4+ helper or CD8+ cytotoxic lymphocytes are reconstituted within 6 and 2 months respectively. 19 Reconstitution of immunoregulatory functions has been less studied but seems to take at least 6 months. 20 Recovery of suppressive T lymphocytes or immunoregulatory function has not been explored in the present or other series and no formal conclusion can be drawn. However, indirect evidence might support the hypothesis that alteration of immunoregulatory functions are disrupted. In most of the present cases and in previous reports, thrombocytopenia occurred less than 1 year after autologous transplant, over the time frame of altered immune reconstitution. 1, 8, 21 The spontaneous remission of autoimmune manifestations after the period necessary for a full immunological recovery may also suggest that altered immune reconstitution could be important. Finally, other factors suspected to be involved in impaired T cell functions were also found in some patients: previous fludarabine treatment (known to be associated with occurrence of autoimmune hemolytic anemia 22 ) or use of TBI (which may alter thymic function and recovery or function of regulatory lymphocytes 23, 24 ). The same immunological mechanisms are suspected during autoimmune reactions and after induction of autologous GVHD. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Finally, the lack of lymphoma relapse in the present series, despite the poor prognostic characteristics of those patients, may suggest that a graft-versus-lymphoma effect could be associated with the occurrence of autoimmune events after transplantation. The contribution of autoimmune events in maintaining disease control after ASCT has been previously suspected. 26 Long-term survival of these patients, despite the limited number, should be considered in regard of other observations of autologous GVHD associated with antitumor activity in mice and humans. 7 In patients undergoing ASCT, immunomonitoring with quantitative reconstitution of T-cell regulatory subpopulations (such as CD4+CD25+ lymphocytes) and recovery of T suppressive function should permit a better understanding of immune phenomena. The relation between autoimmune disease, antitumoral effect and immune reconstitution after autologous transplantation should also be considered for further development of immunotherapy after ASCT.
